ATLANTA, GA February 19, 2013 – The NeuroBiology Foundation announces today the launch of a new non-profit medical research foundation dedicated to the advancement of research in Schizophrenia and Bipolar Disorder. The Foundation is committed to facilitating highly effective clinical solutions to help treat these devastating conditions through funded research using the most sophisticated scientific tools and method.
Approximately 114 million people live with Schizophrenia or Bipolar Disorder globally and the number of American adults affected is approximately 5 million. Today’s treatment options for these illnesses, that represent two of the most difficult to treat serious mental illnesses, often have only a moderate degree of effectiveness. They are associated with many side effects and poor patient compliance. With current research funding in the US for Schizophrenia and Bipolar Disorder at the disproportionately low level of less than 1% of available medical research funds, Jeremy D. Ollerenshaw, Ph.D., Executive Director and Founder of the NeuroBiology Foundation, has established the new 501(c)(3) non-profit scientific and clinical research organization to specifically address this imbalance by providing research grants nationwide to qualifying scientists and clinicians to reveal new therapeutic targets to direct better treatments for Schizophrenia and Bipolar Disorder. The Foundation intends to leverage significant recent advances within the neuroscience disciplines to break new ground in its research objectives.
About the NeuroBiology Foundation The NeuroBiology Foundation is a 501(c)(3) non-profit organization awarding scientific and clinical research grants to gain better understand the neurobiology of Schizophrenia and Bipolar Disorder, and to target new opportunities for development of more effective therapeutics with fewer side effects. The Foundation and its Board of Directors has established its Scientific Advisory Board that comprises a widely published and highly respected body of scientific and clinical expertise in order to provide guidance and focus for its research programs in the neurobiology of Schizophrenia and Bipolar Disorder.